Pomerantz Law Firm Investigates PepGen Inc. Over Securities Fraud Claims

Date: April 2, 2026
Location: New York

In a significant move aimed at protecting investors, the Pomerantz Law Firm has launched an investigation into allegations of securities fraud concerning PepGen Inc. (NASDAQ: PEPG). This inquiry comes on the heels of troubling news announced by PepGen regarding a setback in its clinical trial program, which has already impacted the Company’s stock price dramatically.

On March 4, 2026, PepGen disclosed that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on its FREEDOM2-DM1 Phase 2 study. This trial focuses on PGN-EDODM1, intended for patients with myotonic dystrophy type 1 (DM1). The FDA's partial hold raised concerns about previously submitted pharmacology and toxicology studies, which can have far-reaching implications for the company’s future trials and overall viability.

The news had an immediate and adverse effect on PepGen’s stock, which plummeted by $1.25, or 18.57%, closing at $5.50 on March 5, 2026. This key event has led investors to question whether there had been any misrepresentation or failures in compliance with federal regulations by PepGen's management.

Pomerantz LLP, a well-respected name in corporate and securities law, encourages affected investors to reach out for further information on possibly joining a class action lawsuit. The firm is renowned for its role in advocating for investors’ rights, especially in cases of securities fraud and corporate misconduct. Founded by the late Abraham L. Pomerantz, the firm has a long history of achieving favorable outcomes for its clients, including numerous multimillion-dollar recovery awards.

According to Danielle Peyton, a representative at Pomerantz, investors who may be affected or have inquiries about PepGen’s situation are urged to contact the firm directly via phone or email. Legal action is an avenue that is often pursued when companies withhold critical information or fail to comply with legal standards, and Pomerantz is at the forefront of this fight.

What Investors Should Know

Investing in biotech companies can be particularly volatile due to the uncertain and highly regulated nature of drug development. Events such as clinical trial holds can indicate larger issues within a company's operational framework or pipeline efficiency. Fundamentals can shift in moments—sometimes leading to stock value erosion.

Investors are advised to keep a vigilant eye on press releases from PepGen and additional disclosures that may provide more clarity about the status of the clinical trials and how the company intends to address the FDA’s concerns. The potential for a strategy shift or a recovery plan is paramount for stakeholders hoping to mitigate losses incurred from recent stock fluctuations.

Moreover, it’s essential for existing investors to weigh their options carefully. Seeking legal counsel can provide insight into the next steps—whether they wish to regroup with fellow investors for collective action or take individual measures.

Conclusion

As this situation continues to evolve, it serves as a reminder of the risks inherent in investing, particularly in sectors like biotechnology where the stakes are high and regulatory scrutiny is intense. Pomerantz LLP has been a beacon for investors navigating these tumultuous waters, proving that they stand firm against securities fraud. Investors are encouraged to stay informed, work with legal professionals, and act decisively in the face of adverse market reactions. PepGen’s next steps will undoubtedly be watched closely by the market and all its stakeholders.

For more information on this investigation or to contact Pomerantz, reach out to Danielle Peyton directly at 646-581-9980 or via email at [email protected].